Details of the Drug

General Information of Drug (ID: DMDZ9LT)

Drug Name
Ethosuximide
Synonyms
Aethosuccimidum; Aethosuximide; Asamid; Atysmal; Capitus; Emeside; Ethosuccimid; Ethosuccimide; Ethosuccinimide; Ethosuxide; Ethosuximidum; Ethylmethylsuccimide; Ethymal; Etomal; Etosuccimide; Etosuximid; Etosuximida; Etosuximide; Mesentol; Pemal; Pemalin; Pentinimid; Peptinimid; Petinimid; Petnidan; Piknolepsin; Pyknolepsinum; Ronton; Simatin; Succimal; Succimitin; Suksilep; Suxilep; Suximal; Suxin; Suxinutin; Thetamid; Thilopemal; Zaraondan; Zarodan; Zarondan; Zarontin; Zartalin; Aethosuximide [German]; Desitin Brand of Ethosuximide; Epileo Petit MAL; Etosuccimide [DCIT]; Etosuximida Faes; Faes Brand of Ethosuximide; Fortbenton Brand of Ethosuximide; Jenapharm Brand of Ethosuximide; Katwijk Brand of Ethosuximide; LAB Brand of Ethosuximide; Parke Davis Brand of Ethosuximide; Pfizer Brand of Ethosuximide; United Drug Brand of Ethosuximide; Warner Lambert Brand of Ethosuximide; Wernigerode Brand of Ethosuximide; Cl 366; E 7138; E0746; H 940; PM 671; CN-10395; Ethosuximidum [INN-Latin]; Etosuximida [INN-Spanish]; Faes, Etosuximida; H-490; N-Ethyl methylsuccinimide; PM-671; Simatin(E); Warner-Lambert Brand of Ethosuximide; Zarondan-Saft; Zarontin (TN); C.I. 366; CN-10,395; Piknole.psi.n; Pyknole.psi.num; Alpha-Ethyl-alpha-methylsuccinimide; Alpha-Methyl-alpha-ethylsuccinimide; Ethosuximide (JP15/USP/INN); Ethosuximide [USAN:INN:BAN:JAN]; Gamma-Methyl-gamma-ethylsuccinimide; Gamma-Methyl-gamma-ethyl-succinimide; Gamma-ethyl-gamma-methyl-succinimide; (+-)-2-Ethyl-2-methylsuccinimide; 2-Ethyl-2-methylsuccinimide; 2-Methyl-2-ethylsuccinimide; 3-Ethyl-3-methyl-2, 5-pyrrolidinedion; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; 3-Ethyl-3-methylpyrrolidine-2,5-dione; 3-Ethyl-3-methylpyrroline-2,5-dione; 3-Ethyl-3-methylsuccinimide; 3-Methyl-3-ethylpyrrolidine-2,5-dione; 3-Methyl-3-ethylsuccinimide
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1], [2]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 141.17
Topological Polar Surface Area (xlogp) 0.4
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 93% [4]
Elimination
25% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 53 hours [5]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 118.29607 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 39.2 mg/mL [3]
Chemical Identifiers
Formula
C7H11NO2
IUPAC Name
3-ethyl-3-methylpyrrolidine-2,5-dione
Canonical SMILES
CCC1(CC(=O)NC1=O)C
InChI
InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
InChIKey
HAPOVYFOVVWLRS-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3291
ChEBI ID
CHEBI:4887
CAS Number
77-67-8
DrugBank ID
DB00593
TTD ID
D0Q4XQ
INTEDE ID
DR0659
ACDINA ID
D00254

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) TT729IR CAC1G_HUMAN Blocker [7], [8], [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2E1 (CYP2E1)
Main DME 		DEVDYN7 CP2E1_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [10]
Cytochrome P450 3A43 (CYP3A43) DEO1IE3 CP343_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ethosuximide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Ethosuximide caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [53]
Cenobamate DMGOVHA Moderate Increased metabolism of Ethosuximide caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [54]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Ethosuximide caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [55]
Rufinamide DMWE60C Moderate Increased metabolism of Ethosuximide caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [56]
Phenobarbital DMXZOCG Moderate Increased plasma concentrations of Ethosuximide and Phenobarbital due to competitive inhibition of the same metabolic pathway. Epilepsy/seizure [8A61-8A6Z] [57]
Coadministration of a Drug Treating the Disease Different from Ethosuximide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased metabolism of Ethosuximide caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [56]
Emapalumab DMZG5WL Moderate Altered metabolism of Ethosuximide due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [56]
Siltuximab DMGEATB Moderate Altered metabolism of Ethosuximide due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [56]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Ethosuximide caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [58]
Posaconazole DMUL5EW Moderate Decreased metabolism of Ethosuximide caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [56]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Ethosuximide caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [59]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Ethosuximide caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [60]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Ethosuximide caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Tucatinib DMBESUA Moderate Decreased metabolism of Ethosuximide caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [62]
Levomilnacipran DMV26S8 Moderate Antagonize the effect of Ethosuximide when combined with Levomilnacipran. Chronic pain [MG30] [63]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Ethosuximide and Olopatadine. Conjunctiva disorder [9A60] [64]
Mifepristone DMGZQEF Moderate Decreased metabolism of Ethosuximide caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [65]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Ethosuximide caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [66]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Ethosuximide and Ethanol. Cystitis [GC00] [64]
MK-8228 DMOB58Q Moderate Decreased metabolism of Ethosuximide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [67]
Aprepitant DM053KT Moderate Decreased metabolism of Ethosuximide caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [68]
Sertraline DM0FB1J Moderate Antagonize the effect of Ethosuximide when combined with Sertraline. Depression [6A70-6A7Z] [63]
Vilazodone DM4LECQ Moderate Antagonize the effect of Ethosuximide when combined with Vilazodone. Depression [6A70-6A7Z] [63]
Paroxetine DM5PVQE Moderate Antagonize the effect of Ethosuximide when combined with Paroxetine. Depression [6A70-6A7Z] [63]
Vortioxetine DM6F1PU Moderate Antagonize the effect of Ethosuximide when combined with Vortioxetine. Depression [6A70-6A7Z] [63]
Milnacipran DMBFE74 Moderate Antagonize the effect of Ethosuximide when combined with Milnacipran. Depression [6A70-6A7Z] [63]
Escitalopram DMFK9HG Moderate Antagonize the effect of Ethosuximide when combined with Escitalopram. Depression [6A70-6A7Z] [63]
Desvenlafaxine DMHD4PE Moderate Antagonize the effect of Ethosuximide when combined with Desvenlafaxine. Depression [6A70-6A7Z] [63]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Ethosuximide and Esketamine. Depression [6A70-6A7Z] [65]
Tazemetostat DMWP1BH Moderate Increased metabolism of Ethosuximide caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [69]
Itraconazole DMCR1MV Moderate Decreased metabolism of Ethosuximide caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [70]
Boceprevir DMBSHMF Moderate Decreased metabolism of Ethosuximide caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [71]
Telaprevir DMMRV29 Moderate Decreased metabolism of Ethosuximide caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [72]
Rifapentine DMCHV4I Moderate Increased metabolism of Ethosuximide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [73]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Ethosuximide caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [74]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Ethosuximide caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Efavirenz DMC0GSJ Moderate Increased metabolism of Ethosuximide caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [76]
Saquinavir DMG814N Moderate Decreased metabolism of Ethosuximide caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [77]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Ethosuximide caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [74]
Conivaptan DM1V329 Moderate Decreased metabolism of Ethosuximide caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [78]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Ethosuximide caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [79]
Brigatinib DM7W94S Moderate Increased metabolism of Ethosuximide caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [80]
Ceritinib DMB920Z Moderate Decreased metabolism of Ethosuximide caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [56]
PF-06463922 DMKM7EW Moderate Increased metabolism of Ethosuximide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [81]
Selpercatinib DMZR15V Moderate Decreased metabolism of Ethosuximide caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [56]
Chloroquine DMSI5CB Moderate Antagonize the effect of Ethosuximide when combined with Chloroquine. Malaria [1F40-1F45] [65]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Ethosuximide when combined with Hydroxychloroquine. Malaria [1F40-1F45] [65]
Idelalisib DM602WT Moderate Decreased metabolism of Ethosuximide caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [82]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Ethosuximide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [56]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Ethosuximide and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [83]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Ethosuximide and Lasmiditan. Migraine [8A80] [84]
Exjade DMHPRWG Moderate Decreased metabolism of Ethosuximide caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [85]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Ethosuximide and Flibanserin. Mood disorder [6A60-6E23] [86]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Ethosuximide and Thalidomide. Multiple myeloma [2A83] [87]
Nilotinib DM7HXWT Moderate Decreased metabolism of Ethosuximide caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [88]
Imatinib DM7RJXL Moderate Decreased metabolism of Ethosuximide caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [89]
Modafinil DMYILBE Minor Increased metabolism of Ethosuximide caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [90]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Ethosuximide and Apraclonidine. Optic nerve disorder [9C40] [91]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Ethosuximide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [92]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Ethosuximide and Dextropropoxyphene. Pain [MG30-MG3Z] [93]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Ethosuximide and Buprenorphine. Pain [MG30-MG3Z] [94]
Abametapir DM2RX0I Moderate Decreased metabolism of Ethosuximide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [95]
Lefamulin DME6G97 Moderate Decreased metabolism of Ethosuximide caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [96]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Ethosuximide caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [97]
Enzalutamide DMGL19D Moderate Increased metabolism of Ethosuximide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [98]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Ethosuximide due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [56]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Ethosuximide and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [99]
Tocilizumab DM7J6OR Moderate Altered metabolism of Ethosuximide due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [56]
Canakinumab DM8HLO5 Moderate Altered metabolism of Ethosuximide due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [56]
Rilonacept DMGLUQS Moderate Altered metabolism of Ethosuximide due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [56]
Golimumab DMHZV7X Moderate Altered metabolism of Ethosuximide due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [56]
Sarilumab DMOGNXY Moderate Altered metabolism of Ethosuximide due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [56]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Ethosuximide caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [100]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Ethosuximide caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [56]
Larotrectinib DM26CQR Moderate Decreased metabolism of Ethosuximide caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [65]
Armodafinil DMGB035 Minor Increased metabolism of Ethosuximide caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [90]
LEE011 DMMX75K Moderate Decreased metabolism of Ethosuximide caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [101]
Pitolisant DM8RFNJ Moderate Increased metabolism of Ethosuximide caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [56]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Ethosuximide caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [102]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Ethosuximide and Tizanidine. Tonus and reflex abnormality [MB47] [103]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Ethosuximide and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [99]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Ethosuximide and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [99]
⏷ Show the Full List of 77 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
FD&C red no. 3 E00629 Not Available Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ethosuximide 250 mg capsule 250 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7182).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040253.
3 BDDCS applied to over 900 drugs
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
8 Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
9 Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001 Mar;415(2-3):141-9.
10 Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
21 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
22 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
23 Drug Interactions Flockhart Table
24 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
25 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
26 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
27 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
28 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
29 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
30 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
31 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
32 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
33 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
34 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
35 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
36 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
37 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
38 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
39 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
40 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
41 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
42 Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
43 Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
44 Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
45 cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001 Feb;59(2):386-92.
46 Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
47 Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
48 Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
49 Pfizer. Product Development Pipeline. March 31 2009.
50 The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
51 Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.
52 Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
53 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
54 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
55 Browne TR, Feldman RG, Buchanan RA, et al. "Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions." Neurology 33 (1983): 414-8. [PMID: 6403891]
56 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
57 Giaccone M, Bartoli A, Gatti G, Marchiselli R, Pisani F, Latella MA, Perucca E "Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients." Br J Clin Pharmacol 41 (1996): 575-9. [PMID: 8799524]
58 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
59 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
60 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
61 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
62 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
63 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
64 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
65 Cerner Multum, Inc. "Australian Product Information.".
66 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
67 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
68 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
69 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
70 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
71 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
72 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
73 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
74 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
75 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
76 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
77 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
78 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
79 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
80 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
81 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
82 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
83 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
84 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
85 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
86 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
87 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
88 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
89 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
90 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
91 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
92 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
93 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
94 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
95 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
96 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
97 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
98 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
99 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
100 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
101 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
102 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
103 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.